The Joint Corp. Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
The Joint Corp (JYNT) PT Raised to $15 at DA Davidson Following 4Q
March 8, 2019 8:52 AM ESTDA Davidson analyst Michael Kawamoto raised the price target on The Joint Corp (NASDAQ: JYNT) to $15.00 (from $10.00) while maintaining a Buy rating following the company's 4Q. JYNT reported 4Q18 revenue, EBITDA, and EPS of $9.1M, $1.5M, and $0.06, compared to consensus of $8.6M, $1.2M, and $0.03.... More
The Joint Corp. (JYNT) Tops Q4 EPS by 3c, Revenues Beat; Offers FY19 Outlook
March 7, 2019 4:31 PM ESTThe Joint Corp. (NASDAQ: JYNT) reported Q4 EPS of $0.06, $0.03 better than the analyst estimate of $0.03. Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.6 million.
Building upon the foundation we laid out over the past two years, we will continue to accelerate franchise sales, further leverage our regional developer (RD) strategy, and step up the expansion of our corporate clinic portfolio... More
